Chemomab Therapeutics Ltd.
Chemomab Therapeutics develops nebokitug, a monoclonal antibody targeting CCL24 for immune-fibrotic diseases.
8-KNov 12Latest SEC filing
Nov 12Latest story
July 2026
Chemomab Therapeutics develops nebokitug, a monoclonal antibody targeting CCL24 for immune-fibrotic diseases.